肝动脉置管化疗灌注联合经肝动脉化疗栓塞术治疗中晚期肝癌及肝转移癌患者的疗效

doi:10.3969/j.issn.1671-7171.2026.05.012

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1108 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 【目的】探讨肝动脉置管化疗灌注(HAIC)联合经肝动脉化疗栓塞术(TACE)治疗中晚期肝癌及肝转移癌患者的临床疗效。【方法】选取2023年4月至2025年5月在本院接受治疗的中晚期肝癌及肝转移癌患者共110例,根据治疗方案不同分为对照组和观察组,每组55例。对照组给予常规TACE治疗,观察组给予TACE联合HAIC治疗。比较两组患者的临床疗效,治疗前后肿瘤指标、肝功能指标以及不良反应发生情况。【结果】观察组的客观缓解率、疾病控制率均高于对照组(P<0.05);治疗后,观察组患者的血清甲胎蛋白水平低于对照组,肿瘤最大直径小于对照组(P<0.05);观察组患者的血清白蛋白水平高于对照组,其他肝功能指标低于对照组(P<0.05);观察组患者的健康状态评分高于对照组(P<0.05)。两组各项不良反应发生率比较,差异均无统计学意义(P>0.05)。【结论】HAIC联合TACE治疗中晚期肝癌及肝转移癌患者,可提高近期疗效,改善患者肝功能及健康状态,且未显著增加不良反应。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	孟丹丹

关键词 ：肝肿瘤, 肿瘤转移, 化学栓塞,治疗性, 肝动脉, 化学疗法,肿瘤,局部灌注

Abstract：【Objective】 To investigate the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma and liver metastases. 【Methods】 A total of 110 patients with advanced hepatocellular carcinoma or liver metastases treated in our hospital between April 2023 and May 2025 were included and divided into a control group and an observation group (n=55 in each group) according to different treatment regimens. The control group was treated with conventional TACE, whereas the observation group received TACE combined with HAIC. Clinical efficacy, tumor-related markers, liver function parameters, and the incidence of adverse reactions before and after treatment were compared between the two groups. 【Results】 The objective response rate and disease control rate in the observation group were higher than those in the control group (P<0.05). After treatment, serum alpha-fetoprotein levels and maximum tumor diameter were lower in the observation group compared with the control group (P<0.05). Liver function parameters in the observation group were lower, whereas serum albumin levels were higher than those in the control group (P<0.05). Health status scores of patients in the observation group were higher than those in the control group (P<0.05). No statistically significant differences were observed in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 HAIC combined with TACE improves short-term efficacy and enhances liver function and functional status in patients with advanced hepatocellular carcinoma and liver metastases without significantly increasing adverse reactions.

Key words： Liver Neoplasms Neoplasm Metastasis Chemoembolization, Therapeutic Hepatic Artery Chemotherapy, Cancer, Regional Perfusion

收稿日期: 2025-11-25

中图分类号:

R735.7

引用本文:

孟丹丹. 肝动脉置管化疗灌注联合经肝动脉化疗栓塞术治疗中晚期肝癌及肝转移癌患者的疗效[J]. 医学临床研究, 2026, 43(5): 746-749.
MENG Dandan. Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with Transarterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma and Liver Metastases. JOURNAL OF CLINICAL RESEARCH, 2026, 43(5): 746-749.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2026.05.012 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2026/V43/I5/746

[1] 王立坤,陈曦,武雪亮,等. 超声造影鉴别诊断原发性肝癌和结直肠癌肝转移的临床研究[J].影像科学与光化学,2025,43(3):5-12.
[2] 杜廷伟,原高明,刘鹤阳. 冷循环射频消融联合¹²⁵I粒子植入、TACE对中期巨块型肝癌的治疗效果[J].肝脏,2025,30(10):1326-1329.
[3] 朱恒美,肖红梅,房树恒,等. 肝动脉灌注化疗肝癌患者留置管路并发症预防管理最佳证据总结[J].介入放射学杂志,2025,34(4):425-429.
[4] 邢通潮,祝普利,尹超,等. Child-Pugh分级对经肝动脉化疗栓塞联合射频消融术治疗的肝细胞癌患者预后的影响[J].中国肝脏病杂志(电子版),2018,10(3):27-31.
[5] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009, 45(2): 228-247.
[6] MARINA O, SUH J H, REDDY C A, et al. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution[J].J Neurosurgery,2011, 115(2): 220-229.
[7] 张志坚,雷志丹.多层螺旋CT在诊断鉴别肝转移瘤、原发性肝癌患者中的应用[J].中国CT和MRI杂志,2018,16(5):90-93.
[8] LU H H, LIANG B, ZHENG C S, et al. Efficacy and safety analysis of D-TACE combined with lenvatinib in the treatment of hepatocellular carcinoma refractory to C-TACE[J].BMC gastroenterol,2025, 25(1): 817.
[9] SI T, HUANG Z, KHORSANDI S E, et al. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: a systematic review with meta-analysis[J].Frontiers Bioeng Biotechnol,2022, 10: 1010824.
[10] 张成佳,邵泽锋,张本善. 肝动脉灌注化疗联合栓塞介入治疗原发性肝癌的疗效[J].医学临床研究,2020,37(4):595-597.
[11] 孙冰,冯坤鹏,王兴龙,等. 基于CT灌注参数评价肝癌患者TACE联合射频消融治疗早期治疗反应的价值[J].中国CT和MRI杂志,2025,23(9):116-119.
[12] YUE R B, LIU X. Impact of transarterial chemoembolization or hepatic artery infusion chemotherapy on liver function after hepatocellular carcinoma resection: an observational study[J].Digestion,2023, 104(4): 291-298.
[13] LI Q J, HE M K, CHEN H W, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase Ⅲ trial[J].J Clin Oncol,2022, 40(2): 150-160.
[14] YANG J, SHANG X, LI J, et al. Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma[J].J Gastrointest Oncol,2024, 15(1): 346.